Glycan-based biomarkers for mucopolysaccharidoses

Molecular Genetics and Metabolism

Volumn 111, Issue 2, 2014, Pages 73-83

  Lawrence, Roger ^a   Brown, Jillian R ^b   Lorey, Fred ^c   Dickson, Patricia I ^d   Crawford, Brett E ^b   Esko, Jeffrey D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Zacharon Pharmaceuticals Inc   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Carbohydrate biomarkers; Glycosaminoglycans; Lysosomal storage disorders; Mass spectrometry; Mucopolysaccharidoses; Sensi Pro assay

Indexed keywords

CHONDROITIN; DERMATAN SULFATE; DYE; GLYCAN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HYALURONIC ACID; KERATAN SULFATE; LYSOSOME ENZYME; OLIGOSACCHARIDE;

CELL CULTURE; DRIED BLOOD SPOT TESTING; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME MODIFICATION; ENZYME REPLACEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MORQUIO SYNDROME; MUCOPOLYSACCHARIDOSIS; NEWBORN SCREENING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING ASSAY; REVIEW;

ANIMALIA; BACTERIA (MICROORGANISMS);

CARBOHYDRATE BIOMARKERS; GLYCOSAMINOGLYCANS; LYSOSOMAL STORAGE DISORDERS; MASS SPECTROMETRY; MUCOPOLYSACCHARIDOSES; SENSI-PRO ASSAY;

ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; DISEASE MODELS, ANIMAL; DRIED BLOOD SPOT TESTING; ENZYME ASSAYS; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; MASS SPECTROMETRY; MUCOPOLYSACCHARIDOSES; OXIDATION-REDUCTION;

EID: 84893709837     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.07.016     Document Type: Review

References (89)

1. Lysosomal Disorders. Metabolic and Molecular Basis of Inherited Disease 2001, 3371-3896. MacGraw-Hill, San Francisco. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler, B. Vogelstein (Eds.).
2. Bouwman M.G., Teunissen Q.G., Wijburg F.A., Linthorst G.E. 'Doctor Google' ending the diagnostic odyssey in lysosomal storage disorders: parents using internet search engines as an efficient diagnostic strategy in rare diseases. Arch. Dis. Child. 2010, 95:642-644.
3. Neufeld E.F., Muenzer J. The Mucopolysaccharidoses. Metabolic and Molecular Basis of Inherited Disease 2001, 3421-3452. MacGraw-Hill, San Francisco. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler, B. Vogelstein (Eds.).
4. Peterson S., Liu J. Deciphering mode of action of heparanase using structurally defined oligosaccharides. J. Biol. Chem. 2012, 287:34836-34843.
5. Kaneiwa T., Mizumoto S., Sugahara K., Yamada S. Identification of human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccharide sequence. Glycobiology 2010, 20:300-309.
6. Giugliani R., Federhen A., Rojas M.V., Vieira T., Artigalas O., Pinto L.L., Azevedo A.C., Acosta A., Bonfim C., Lourenco C.M., Kim C.A., Horovitz D., Bonfim D., Norato D., Marinho D., Palhares D., Santos E.S., Ribeiro E., Valadares E., Guarany F., de Lucca G.R., Pimentel H., de Souza I.N., Correa J.N., Fraga J.C., Goes J.E., Cabral J.M., Simionato J., Llerena J., Jardim L., Giuliani L., da Silva L.C., Santos M.L., Moreira M.A., Kerstenetzky M., Ribeiro M., Ruas N., Barrios P., Aranda P., Honjo R., Boy R., Costa R., Souza C., Alcantara F.F., Avilla S.G., Fagondes S., Martins A.M. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet. Mol. Biol. 2010, 33:589-604.
7. Lau A.A., Hannouche H., Rozaklis T., Hassiotis S., Hopwood J.J., Hemsley K.M. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. Exp. Neurol. 2010, 225:445-454.
8. Church H., Tylee K., Cooper A., Thornley M., Mercer J., Wraith E., Carr T., O'Meara A., Wynn R.F. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 2007, 39:207-210.
9. Pan D. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses. Curr. Pharm. Biotechnol. 2011, 12:884-896.
10. de Ruijter J., Valstar M.J., Wijburg F.A. Mucopolysaccharidosis Type III (Sanfilippo syndrome): emerging treatment strategies. Curr. Pharm. Biotechnol. 2011, 12:923-930.
11. Jakobkiewicz-Banecka J., Piotrowska E., Gabig-Ciminska M., Borysiewicz E., Slominska-Wojewodzka M., Narajczyk M., Wegrzyn A., Wegrzyn G. Substrate reduction therapies for mucopolysaccharidoses. Curr. Pharm. Biotechnol. 2011, 12:1860-1865.
12. Valayannopoulos V., Wijburg F.A. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50:49-59.
13. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50:4-12.
14. Neufeld E.F. Enzyme replacement therapy - a brief history. Fabry Disease: Perspectives from 5 Years of FOS 2006, Oxford PharmaGenesis, Oxford. A. Mehta, M. Beck, G. Sunder-Plassmann (Eds.).
15. Dickson P.I. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int. J. Clin. Pharmacol. Ther. 2009, 47:124-127.
16. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
17. Wraith E.J., Hopwood J.J., Fuller M., Meikle P.J., Brooks D.A. Laronidase treatment of mucopolysaccharidosis I. BioDrugs 2005, 19:1-7.
18. Lawrence R., Brown J.R., Al-Mafraji K., Lamanna W.C., Beitel J.R., Boons G.J., Esko J.D., Crawford B.E. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat. Chem. Biol. 2012, 8:197-204.
19. Hemsley K.M., Hopwood J.J. Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J. Inherit. Metab. Dis. 2010, 33:363-371.
20. Aerts J.M., Kallemeijn W.W., Wegdam W., Joao Ferraz M., van Breemen M.J., Dekker N., Kramer G., Poorthuis B.J., Groener J.E., Cox-Brinkman J., Rombach S.M., Hollak C.E., Linthorst G.E., Witte M.D., Gold H., van der Marel G.A., Overkleeft H.S., Boot R.G. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J. Inherit. Metab. Dis. 2011, 34:605-619.
21. Lehman T.J., Miller N., Norquist B., Underhill L., Keutzer J. Diagnosis of the mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50:41-48.
22. Clarke L.A., Winchester B., Giugliani R., Tylki-Szymanska A., Amartino H. Biomarkers for the mucopolysaccharidoses: Discovery and clinical utility. Mol. Genet. Metab. 2012, 106:395-402.
23. Adamczyk B., Tharmalingam T., Rudd P.M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 2012, 1820:1347-1353.
24. Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
25. Valstar M.J., Neijs S., Bruggenwirth H.T., Olmer R., Ruijter G.J., Wevers R.A., van Diggelen O.P., Poorthuis B.J., Halley D.J., Wijburg F.A. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann. Neurol. 2010, 68:876-887.
26. Whitley C.B., Ridnour M.D., Draper K.A., Dutton C.M., Neglia J.P. Diagnostic test for mucopolysaccharidosis I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin. Chem. 1989, 35:374-379.
27. de Jong J.G., Wevers R.A., Laarakkers C., Poorthuis B.J. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin. Chem. 1989, 35:1472-1477.
28. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Sidman M., Kakkis E.D., Cox G.F. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123:229-240.
29. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 2006, 8:465-473.
30. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.
31. Davies N.P., Roubin R.H., Whitelock J.M. Characterization and purification of glycosaminoglycans from crude biological samples. J. Agric. Food Chem. 2008, 56:343-348.
32. Chih-Kuang C., Shuan-Pei L., Shyue-Jye L., Tuen-Jen W. MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in Sanfilippo and Morquio syndromes. J. Clin. Lab. Anal. 2002, 16:253-258.
33. de Jong J.G., Heijs W.M., Wevers R.A. Mucopolysaccharidoses screening: dimethylmethylene blue versus alcian blue. Ann. Clin. Biochem. 1994, 31:267-271.
34. Mabe P., Valiente A., Soto V., Cornejo V., Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin. Chim. Acta 2004, 345:135-140.
35. Lage S., Prieto J.A., Andrade F., Sojo A., Sanjurjo P., Aldamiz-Echevarria L.J. Reliability of a visual test for the rapid detection of mucopolysaccharidoses: GAG-test((R)). J. Clin. Lab. Anal. 2011, 25:179-184.
36. Tomatsu S., Gutierrez M.A., Ishimaru T., Pena O.M., Montano A.M., Maeda H., Velez-Castrillon S., Nishioka T., Fachel A.A., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Isogai K., Suzuki Y., Orii T., Noguchi A. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005, 28:743-757.
37. Hintze J.P., Tomatsu S., Fujii T., Montano A.M., Yamaguchi S., Suzuki Y., Fukushi M., Ishimaru T., Orii T. Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine. Biomark. Insights 2011, 6:69-78.
38. Ambrosius M., Kleesiek K., Gotting C. Quantitative determination and comparison of the glycosaminoglycan Delta-disaccharide composition in 22 different human cell lines. Cell Biol. Int. 2009, 33:848-852.
39. Oguma T., Tomatsu S., Montano A.M., Okazaki O. Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ion spray ionization tandem mass spectrometry. Anal. Biochem. 2007, 368:79-86.
40. Tomatsu S., Montano A.M., Oguma T., Dung V.C., Oikawa H., Gutierrez M.L., Yamaguchi S., Suzuki Y., Fukushi M., Barrera L.A., Kida K., Kubota M., Orii T. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Mol. Genet. Metab. 2010, 99:124-131.
41. Wei W., Ninonuevo M.R., Sharma A., Danan-Leon L.M., Leary J.A. A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum. Anal. Chem. 2011, 83:3703-3708.
42. Holley R.J., Deligny A., Wei W., Watson H.A., Ninonuevo M.R., Dagalv A., Leary J.A., Bigger B.W., Kjellen L., Merry C.L. Mucopolysaccharidosis type I: Unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking alpha-L-iduronidase. J. Biol. Chem. 2011, 286:37515-37524.
43. Maccarana M., Casu B., Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 1993, 268:23898-23905.
44. Bai X.M., Esko J.D. An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation. J. Biol. Chem. 1996, 271:17711-17717.
45. Crawford B.E., Garner O.B., Bishop J.R., Zhang D.Y., Bush K.T., Nigam S.K., Esko J.D. Loss of the heparan sulfate sulfotransferase, Ndst1, in mammary epithelial cells selectively blocks lobuloalveolar development in mice. PLoS One 2010, 5:e10691.
46. Lortat-Jacob H., Kleinman H.K., Grimaud J.A. High-affinity binding of interferon-gamma to a basement membrane complex (matrigel). J. Clin. Invest. 1991, 87:878-883.
47. Salmivirta M., Safaiyan F., Prydz K., Andresen M.S., ARyan M., Kolset S.O. Differentiation-associated modulation of heparan sulfate structure and function in CaCo-2 colon carcinoma cells. Glycobiology 1998, 8:1029-1036.
48. Maccarana M., Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology 1993, 3:271-277.
49. Randall D.R., Sinclair G.B., Colobong K.E., Hetty E., Clarke L.A. Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol. Genet. Metab. 2006, 88:235-243.
50. Halldorsdottir A.M., Zhang L., Tollefsen D.M. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate. Glycobiology 2006, 16:693-701.
51. Tollefsen D.M. Heparin cofactor II modulates the response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 2007, 27:454-460.
52. Langford-Smith K.J., Mercer J., Petty J., Tylee K., Church H., Roberts J., Moss G., Jones S., Wynn R., Wraith J.E., Bigger B.W. Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J. Inherit. Metab. Dis. 2011, 34:499-508.
53. Randall D.R., Colobong K.E., Hemmelgarn H., Sinclair G.B., Hetty E., Thomas A., Bodamer O.A., Volkmar B., Fernhoff P.M., Casey R., Chan A.K., Mitchell G., Stockler S., Melancon S., Rupar T., Clarke L.A. Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol. Genet. Metab. 2008, 94:456-461.
54. Clarke L.A., Hemmelgarn H., Colobong K., Thomas A., Stockler S., Casey R., Chan A., Fernoff P., Mitchell J. Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients. J. Inherit. Metab. Dis. 2012, 35:355-362.
55. Whiteman P. Prenatal diagnosis of mucopolysaccharidoses. Lancet 1973, 1:1249.
56. Wynn R.F., Wraith J.E., Mercer J., O'Meara A., Tylee K., Thornley M., Church H.J., Bigger B.W. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J. Pediatr. 2009, 154:609-611.
57. Fuller M., Meikle P.J., Hopwood J.J. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology 2004, 14:443-450.
58. King B., Savas P., Fuller M., Hopwood J., Hemsley K. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. Mol. Genet. Metab. 2006, 87:107-112.
59. Hopwood J.J., Elliott H. N-acetylglucosamine 6-sulfate residues in keratan sulfate and heparan sulfate are desulfated by the same enzyme. Biochem. Int. 1983, 6:141-148.
60. Hopwood J.J., Elliott H. Isolation and characterization of N-acetylglucosamine 6-sulfate from the urine of a patient with Sanfilippo type D syndrome and its occurrence in normal urine. Biochem. Int. 1983, 6:831-836.
61. Hopwood J.J., Elliott H. Urinary excretion of sulphated N-acetylhexosamines in patients with various mucopolysaccharidoses. Biochem. J. 1985, 229:579-586.
62. Ramsay S.L., Meikle P.J., Hopwood J.J. Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry. Mol. Genet. Metab. 2003, 78:193-204.
63. de Ruijter J., Ijlst L., Kulik W., van Lenthe H., Wagemans T., van Vlies N., Wijburg F.A. Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease. J. Inherit. Metab. Dis. 2013, 36:271-279.
64. de Ruijter J., de Ru M.H., Wagemans T., Ijlst L., Lund A.M., Orchard P.J., Schaefer G.B., Wijburg F.A., van Vlies N. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. Mol. Genet. Metab. 2012, 107:705-710.
65. Tomatsu S., Montano A.M., Oguma T., Dung V.C., Oikawa H., de Carvalho T.G., Gutierrez M.L., Yamaguchi S., Suzuki Y., Fukushi M., Sakura N., Barrera L., Kida K., Kubota M., Orii T. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J. Inherit. Metab. Dis. 2010, 33:141-150.
66. Tomatsu S., Montano A.M., Oguma T., Dung V.C., Oikawa H., de Carvalho T.G., Gutierrez M.L., Yamaguchi S., Suzuki Y., Fukushi M., Kida K., Kubota M., Barrera L., Orii T. Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J. Inherit. Metab. Dis. 2010, 10.1007/s10545-009-9013-x.
67. Montano A.M., Oikawa H., Tomatsu S., Nishioka T., Vogler C., Gutierrez M.A., Oguma T., Tan Y., Grubb J.H., Dung V.C., Ohashi A., Miyamoto K., Orii T., Yoneda Y., Sly W.S. Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Mol. Genet. Metab. 2008, 94:178-189.
68. Hendriksz C.J., Harmatz P., Beck M., Jones S., Wood T., Lachman R., Gravance C.G., Orii T., Tomatsu S. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol. Genet. Metab. 2013, 110:54-64.
69. Linhardt R.J., Galliher P.M., Cooney C.L. Polysaccharide lyases. Appl. Biochem. Biotechnol. 1986, 12:135-176.
70. Byers S., Rozaklis T., Brumfield L.K., Ranieri E., Hopwood J.J. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Mol. Genet. Metab. 1998, 65:282-290.
71. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., Stanley P. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999, 9:1389-1396.
72. Lawrence R., Olson S.K., Steele R.E., Wang L., Warrior R., Cummings R.D., Esko J.D. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J. Biol. Chem. 2008, 283:33674-33684.
73. Xia B., Feasley C.L., Sachdev G.P., Smith D.F., Cummings R.D. Glycan reductive isotope labeling for quantitative glycomics. Anal. Biochem. 2009, 387:162-170.
74. Staples G.O., Shi X., Zaia J. Extended N-sulfated domains reside at the nonreducing end of heparan sulfate chains. J. Biol. Chem. 2010, 285:18336-18343.
75. Lamanna W.C., Lawrence R., Sarrazin S., Lameda-Diaz C., Gordts P.L., Moremen K.W., Esko J.D. A genetic model of substrate reduction therapy for mucopolysaccharidosis. J. Biol. Chem. 2012, 287:36283-36290.
76. Tomatsu S., Okamura K., Taketani T., Orii K.O., Nishioka T., Gutierrez M.A., Velez-Castrillon S., Fachel A.A., Grubb J.H., Cooper A., Thornley M., Wraith E., Barrera L.A., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Isogai K., Suzuki Y., Orii T., Kondo N., Creer M., Noguchi A. Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr. Res. 2004, 55:592-597.
77. Martell L.A., Cunico R.L., Ohh J., Fulkerson W., Furneaux R., Foehr E.D. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis 2011, 3:1855-1866.
78. Tomatsu S., Okamura K., Maeda H., Taketani T., Castrillon S.V., Gutierrez M.A., Nishioka T., Fachel A.A., Orii K.O., Grubb J.H., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Haskins M., Isogai K., Suzuki Y., Orii T., Kondo N., Creer M., Okuyama T., Tanaka A., Noguchi A. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005, 28:187-202.
79. Ramsay S.L., Maire I., Bindloss C., Fuller M., Whitfield P.D., Piraud M., Hopwood J.J., Meikle P.J. Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases. Mol. Genet. Metab. 2004, 83:231-238.
80. Meikle P.J., Ranieri E., Simonsen H., Rozaklis T., Ramsay S.L., Whitfield P.D., Fuller M., Christensen E., Skovby F., Hopwood J.J. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics 2004, 114:909-916.
81. Langford-Smith K., Arasaradnam M., Wraith J.E., Wynn R., Bigger B.W. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Mol. Genet. Metab. 2010, 99:269-274.
82. Malinowska M., Wilkinson F.L., Langford-Smith K.J., Langford-Smith A., Brown J.R., Crawford B.E., Vanier M.T., Grynkiewicz G., Wynn R.F., Wraith J.E., Wegrzyn G., Bigger B.W. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010, 5:e14192.
83. Dickson P.I., Ellinwood N.M., Brown J.R., Witt R.G., Le S.Q., Passage M.B., Vera M.U., Crawford B.E. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I. Mol. Genet. Metab. 2012, 106:68-72.
84. Lamanna W.C., Lawrence R., Sarrazin S., Esko J.D. Secondary storage of dermatan sulfate in Sanfilippo disease. J. Biol. Chem. 2011, 286:6955-6962.
85. Diez-Roux G., Ballabio A. Sulfatases and human disease. Annu. Rev. Genomics Hum. Genet. 2005, 6:355-379.
86. Abitbol M., Thibaud J.L., Olby N.J., Hitte C., Puech J.P., Maurer M., Pilot-Storck F., Hedan B., Dreano S., Brahimi S., Delattre D., Andre C., Gray F., Delisle F., Caillaud C., Bernex F., Panthier J.J., Aubin-Houzelstein G., Blot S., Tiret L. A canine Arylsulfatase G (ARSG) mutation leading to a sulfatase deficiency is associated with neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14775-14780.
87. Kowalewski B., Lamanna W.C., Lawrence R., Damme M., Stroobants S., Padva M., Kalus I., Frese M.A., Lubke T., Lullmann-Rauch R., D'Hooge R., Esko J.D., Dierks T. Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10310-10315.
88. Varki A., Cummings R.D., Esko J.D., Freeze H.H., Stanley P., Marth J.D., Bertozzi C.R., Hart G.W., Etzler M.E. Symbol nomenclature for glycan representation. Proteomics 2009, 9:5398-5399.
89. Lawrence R., Lu H., Rosenberg R.D., Esko J.D., Zhang L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat. Methods 2008, 5:291-292.